2003 CBCRP Application Evaluation & Review Committees
Grant applications were initially reviewed and scored for scientific merit in six peer review committees. The CBCRP committees are composed of scientists and advocates from around the world. Grants are evaluated using a model that follows established practice at the National Institutes of Health (NIH). The committee chair leads the review process and is a senior researcher in breast cancer areas associated with the committee's central topic or priority issue. Committee members have broad expertise in topics associated with individual applications. Breast cancer advocate reviewers are women active in breast cancer issues (many of whom are also living with the disease), and they bring their personal knowledge and commitment to the review process. Often the advocates have specialized training in grant review, such as the NBCC's Project LEAD. Each committee includes a California Advocate observer, who is not assigned applications for review and does not vote, but represents the California advocacy community. The observer gains insight into the research evaluation process and provides feedback to the Program on this process. Ad Hoc members participate by teleconference and bring their specialized expertise to the review of individual applications.
Over the past five years, the CBCRP has developed, tested, and phased in a scoring system that allows our expert reviewers to better differentiate applications that are especially innovative and that have the most potential impact on breast cancer. This has improved our ability to choose the most innovative and creative research for funding. In the past, the majority of research funding agencies, including the CBCRP and the NIH, rated proposals with a single scientific merit score. With this method, for example, an application with an excellent research plan to test an idea that wasn't particularly novel could receive the same score as an application with an average research plan to test a very novel idea. CBCRP's new scoring method, which separates scientific merit into component elements specific for each award type, can better differentiate specific qualities in each application. Some key scientific merit components include:
- Innovativeness
- Impact
- Approach
- Feasibility
- Career Development
In addition, we place some of our Priority Issues and Award Types into a “primary” category, and these applications are given first consideration for funding.
Finally, the advisory Council recommends the grants to be funded, based upon (1) the review committee scientific average and component merit scores and (2) the programmatic relevance. This two-tiered process ensures both scientific excellence and relevance of the research to CBCRP's mission and goals.
The CBCRP wishes to thank the participants in our 2003 Review Committees for their service and dedication to our Program.
Basic Breast Biology Committee
|
Chair Members James DiRenzo, Ph.D. Priscilla Furth, M.D. Russell Hovey, Ph.D. Sofia D. Merajver, M.D., Ph.D. M. Stephen Meyn, M.D., Ph.D., FRCP |
A. James Mixson, M.D. Leslie V. Parise, Ph.D. Jeffrey W. Pollard, Ph.D. Fazlul H. Sarkar, Ph.D. George P. Tuszynski, Ph.D. Ning Zheng, Ph.D. Advocate Members |
Selma J. Morris, M.Ed. Karin Noss, M.A., M.P.A. California Advocate Observer Member Ad-Hoc Members Thomas P. Quinn, Ph.D. Steven E. Shoelson, M.D., Ph.D. |
Community Resource Collaboration Concept Paper
|
Chair Members Deborah Bowen, Ph.D. |
Karen H. Dow, Ph.D. Frances Marcus Lewis, Ph.D. John K. Worden, Ph.D. |
Advocate Member Ad-Hoc Members Charles L. Shapiro, MD |
Community Resource Collaboration and Sociocultural, Behavioral, and Psychological Committee
|
Chair Members Mary Anglin, Ph.D., M.P.H. Deborah Bowen, Ph.D. Janet S. Carpenter, Ph.D., RN Karen H. Dow, Ph.D. Kathryn M. Kash, Ph.D |
Nancy Keating, M.D. Paula M. Lantz, Ph.D. Susan K. Lutgendorf, Ph.D. Electra D. Paskett, Ph.D. Marc D. Schwartz, Ph.D. Charles L. Shapiro, MD Sally W. Vernon, Ph.D. |
John K. Worden, Ph.D. Advocate Members Harriet B. Eggert Deborah L. Hampton California Advocate Observer Member Ad-Hoc Members George Wright, Ph.D. |
Etiology and Prevention Committee
|
Chair Members Jonine L. Bernstein, Ph.D. Abeena M. Brewster, M.D., M.H.S. Laurence M. Demers, Ph.D. Zora Djuric, Ph.D. Marilie D. Gammon, Ph.D. |
Marc T. Goodman, Ph.D., M.P.H. Adrian V. Lee, Ph.D. Kathi Malone, Ph.D. Daniel Medina, Ph.D. Tom Sellers, Ph.D. Patricia A. Thompson, Ph.D. Andrew T. Vaughan, Ph.D. |
Douglas Yee, M.D. Advocate Members Cynthia Geoghegan Kim O'Meara California Advocate Observer Member Ad-Hoc Members Wanda Pratt, Ph.D. Martin J. Yaffe, Ph.D |
Innovative Treatments and Earlier Detection Committee
|
Chair Members Ben O. Anderson, M.D. Stephen Barnes, Ph.D. Ralph J. Bernacki, Ph.D. Rosalyn Blumenthal, Ph.D. David K. Bol, Ph.D. Esteban Celis, M.D., Ph.D. |
Leslie Gunatilaka, Ph.D. Kathryn A. Morton, M.D. Brian W. Pogue, Ph.D. Janet E. Price, Ph.D. Edward R. Sauter, M.D., Ph.D. Theresa V. Strong, Ph.D. David A. Talmage, Ph.D. Nancy S. Templeton, Ph.D. |
Advocate Members K. Brenda MacGibbon-Taylor, Ph.D. Vicki Tosher Candice Zito-Gilhooly California Advocate Observer Member Ad-Hoc Members Mark A. Green, Ph.D. |
Pathogenesis Committee
|
Chair Members Michael S. Kinch, Ph.D. Richard C. Kurten, Ph.D. Michael T. Lewis, Ph.D. Zheng-gang Liu, Ph.D. |
James Manfredi, Ph.D. James B. McCarthy, Ph.D. Steffi Oesterreich, Ph.D. Susan E. Pories, MD, FACS Richard Poulin, Ph.D. Carla Van Den Berg, Pharm.D. |
Danny R. Welch, Ph.D. Bart Williams, Ph.D. Advocate Members Diane L. Roth Sandra Stanford California Advocate Observer Member Ad-Hoc Member |
Tumor Progression Committee
|
Chair Members Robin S. L. Fuchs-Young, Ph.D. Suzanne A.W. Fuqua, Ph.D. Ram Ganapathi, Ph.D. Jeffrey T. Holt, M.D. |
William G. Kerr, Ph.D. Dawn A. Kirschmann, Ph.D. Funmi Olopade, M.D. Peggy L. Porter, M.D. Karin D. Rodland, Ph.D. Patricia Schoenlein, Ph.D. |
Saraswati Sukumar, Ph.D. Erik W. Thompson, Ph.D. Advocate Members Kathleen Harris Brian R. Shappell California Advocate Observer Member |
The mission of the California Breast Cancer Research Program is to eliminate breast cancer by leading innovation in research, communication, and collaboration in the California scientific and lay communities.
